AGENUS INC — Director's Dealing 2020

Jan 10, 2020

SEC Form 4/A — Form 4/A

Issuer: AGENUS INC (AGEN)
CIK: 0001098972
Period of Report: 2019-12-17

Reporting Person: ARMEN GARO H (Director, Chairman and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-17	Common Stock	J	66000	$3.88	Acquired	1362433	Direct
2019-12-17	Common Stock	J	66000	$3.88	Disposed	1296433	Direct
2019-12-19	Common Stock	J	195358	$3.77	Disposed	1101075	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	163046	Indirect

Footnotes

F1: This line represents a new transaction that is being added to the Statement of Changes in Beneficial Ownership as originally filed.

F2: Represents a distribution from the Garo Armen 2018 2 Year AG GRAT.

F3: This line amends and restates Table 1, Line 4 of the Statement of Changes in Beneficial Ownership as originally filed to correct the amount of securities beneficially owned following the reported transaction.

F4: This line amends and restates Table 1, Line 5 of the Statement of Changes in Beneficial Ownership as originally filed to correct the amount of securities beneficially owned following the reported transaction.

F5: This line amends and restates Table 1, Line 6 of the Statement of Changes in Beneficial Ownership as originally filed to correct the amount of securities beneficially owned following the reported transaction.

F6: Dr. Armen is trustee and has investment authority for the Garo Armen 2018 2 Year AG GRAT holder of 159,000 shares of Agenus common stock. Dr. Armen is Chairman of the Board of Managers and a member of Antigenics LLC ("Antigenics") which as of the date of this report owns 4,046 shares of Agenus Inc. common stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Antigenics and disclaims beneficial ownership to the extent of his pecuniary interest therein.